SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Oct 2, 2026	Oct 2, 2026	View filing
4	Sep 29, 2026	Sep 29, 2026	View filing
4	Sep 25, 2026	Sep 25, 2026	View filing
4	Aug 28, 2026	Aug 28, 2026	View filing
144	Aug 26, 2026	Aug 26, 2026	View filing
10-Q	Aug 3, 2026	Aug 3, 2026	View filing
8-K	Aug 3, 2026	Aug 3, 2026	View filing
S-8	Jul 30, 2026	Jul 30, 2026	View filing
8-K	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 28, 2026	Jul 28, 2026	View filing
4	Jul 8, 2026	Jul 8, 2026	View filing
144	Jul 6, 2026	Jul 6, 2026	View filing
144	Jul 6, 2026	Jul 6, 2026	View filing
8-K	Jun 22, 2026	Jun 22, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 12, 2026	May 12, 2026	View filing
10-Q	May 4, 2026	May 4, 2026	View filing
8-K	May 4, 2026	May 4, 2026	View filing
ARS	Apr 28, 2026	Apr 28, 2026	View filing
DEFA14A	Apr 28, 2026	Apr 28, 2026	View filing
DEF 14A	Apr 28, 2026	Apr 28, 2026	View filing
8-K	Mar 31, 2026	Mar 31, 2026	View filing
4	Feb 26, 2026	Feb 26, 2026	View filing
144	Feb 24, 2026	Feb 24, 2026	View filing
8-K	Feb 23, 2026	Feb 23, 2026	View filing
424B5	Feb 23, 2026	Feb 23, 2026	View filing
S-8	Feb 23, 2026	Feb 23, 2026	View filing

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.

South San Francisco, CA

111 employees

www.oricpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jacob Chacko

View full financials